Today's Low
₹ 146.20
Today's High
₹ 148.50
52 Weeks Low
₹ 107.00
52 Weeks High
₹ 174.25
Lower
₹ 117.20
Upper
₹ 175.80
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 562.3 | 950.6 | 474.2 | 683.3 | 507.9 | 564.8 | 703.2 | 549.4 | 525.7 | 372.8 | 433.8 | 501.5 |
Total Non-Current Assets | 702.9 | 744.6 | 666.4 | 875.3 | 847.8 | 1,027.6 | 1,070.9 | 1,475.2 | 1,573.5 | 1,739.3 | 1,574.5 | 1,617.0 |
Total Assets | 1,271.2 | 1,735.1 | 1,177.4 | 1,558.5 | 1,355.7 | 1,592.4 | 1,774.1 | 2,024.6 | 2,099.2 | 2,112.1 | 2,008.2 | 2,118.5 |
Total Current Liabilities | 329.7 | 773.8 | 447.2 | 622.1 | 938.3 | 695.5 | 689.1 | 474.8 | 706.0 | 826.8 | 510.0 | 516.5 |
Total Non-Current Liabilities | 99.2 | 85.1 | 960.0 | 740.7 | 70.1 | 591.1 | 718.8 | 1,100.1 | 918.5 | 767.1 | 865.2 | 720.3 |
Shareholder's Funds | 843.6 | 876.6 | -228.7 | 198.8 | 350.4 | 308.7 | 355.7 | 448.6 | 471.3 | 512.7 | 625.7 | 875.1 |
Total Liabilities | 1,271.2 | 1,735.1 | 1,177.4 | 1,558.5 | 1,355.7 | 1,592.4 | 1,774.1 | 2,024.6 | 2,099.2 | 2,112.1 | 2,008.2 | 2,118.5 |
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 4.45, which results in a Negative aspect.
The Industry Price to BV stands at 6.03, vs the Price to BV of 0.99, which results in a Negative aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 0.86, which results in a Negative aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 1.10, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 460.0 | 661.2 | 624.8 | 544.1 | 456.7 | 592.8 | 544.0 | 653.1 | 687.2 | 510.0 | 608.5 | 710.1 |
Total Expenditure | 557.9 | 674.4 | 548.2 | 518.6 | 589.8 | 508.3 | 496.9 | 541.4 | 643.3 | 592.0 | 694.6 | 796.4 |
Operating Profit(Excl OI) | -46.3 | -2.2 | 86.6 | 55.8 | -128.1 | 92.8 | 93.7 | 132.1 | 72.4 | -66.7 | -80.6 | -77.5 |
Add: Other Income | 51.7 | 11.0 | 10.0 | 30.4 | 5.1 | 8.2 | 46.6 | 20.4 | 28.5 | 15.4 | 5.4 | 8.8 |
Operating Profit | -46.3 | -2.2 | 86.6 | 55.8 | -128.1 | 92.8 | 93.7 | 132.1 | 72.4 | -66.7 | -80.6 | -77.5 |
Less: Interest | 4.4 | 180.8 | 185.3 | 174.0 | 104.8 | 100.6 | 100.9 | 127.3 | 104.5 | 150.3 | 103.8 | 100.7 |
PBDT | -50.7 | -183.1 | -98.7 | -118.1 | -232.9 | -7.8 | -7.2 | 4.7 | -32.2 | -217.0 | -184.4 | -178.2 |
Less: Depreciation Amortization | 39.1 | 43.8 | 45.6 | 44.1 | 55.0 | 58.5 | 68.0 | 73.3 | 67.2 | 71.1 | 86.0 | 77.1 |
PBT & Exceptional Items | -89.9 | -226.9 | -144.3 | -162.3 | -287.9 | -66.4 | -75.2 | -68.6 | -99.4 | -288.1 | -270.4 | -255.3 |
Less: Exceptional Income Expenses | 102.7 | 1,676.2 | 0.0 | -15.4 | 334.0 | 0.0 | 7.7 | 49.7 | 0.0 | 177.1 | 17.3 | 0.0 |
Profit Before Tax | 12.8 | 1,449.4 | -144.3 | -177.7 | 46.1 | -66.4 | -67.5 | -18.9 | -99.4 | -111.0 | -253.1 | -255.3 |
Less: Taxation | 46.6 | 371.0 | 2.0 | 17.0 | 8.6 | 9.9 | -11.0 | 1.9 | 3.1 | 1.7 | -18.8 | -54.2 |
Profit After Tax | -33.8 | 1,078.3 | -146.2 | -194.6 | 37.5 | -76.2 | -56.5 | -20.9 | -102.5 | -112.6 | -234.3 | -201.1 |
Earnings Per Share | -0.5 | 17.6 | -2.4 | -3.2 | 0.6 | -1.2 | -0.9 | -0.3 | -1.7 | -1.8 | -3.8 | -3.4 |
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PAT Growth stands at 32.18, vs the PAT Growth of -618.75, which results in a Negative aspect.
The Industry PAT Margin stands at 9.77, vs the PAT Margin of -35.77, which results in a Negative aspect.
The Industry PE Ratio stands at 42.56, vs the PE Ratio of 0.00, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 12.8 | 1,449.4 | -145.0 | -177.3 | 46.2 | -66.1 | -67.2 | -18.9 | -99.4 | -111.0 | -253.1 | -255.3 |
Tax Paid | -2.5 | -403.7 | -1.0 | -8.7 | 1.8 | -3.9 | 5.0 | 19.1 | -5.7 | -2.5 | -0.4 | -4.8 |
Adjustment | -95.9 | -1,455.0 | 230.9 | 253.0 | -70.6 | 166.6 | 149.6 | 148.8 | 167.5 | 59.9 | 161.2 | 200.4 |
Changes In Working Capital | 12.8 | 1,449.4 | -145.0 | -177.3 | 46.2 | -66.1 | -67.2 | -18.9 | -99.4 | -111.0 | -253.1 | -255.3 |
Cash Flow after changes in Working Capital | -420.0 | 295.3 | 107.8 | -21.8 | 103.0 | 121.9 | 125.7 | 71.6 | 42.9 | 56.2 | -23.7 | 232.9 |
Cash Flow from Operating Activities | -422.5 | -108.4 | 106.8 | -30.5 | 104.8 | 118.0 | 130.7 | 90.7 | 37.2 | 53.7 | -24.0 | 228.1 |
Cash Flow from Investing Activities | 430.3 | 1,282.6 | -47.7 | -34.8 | -5.3 | 55.3 | -25.8 | 16.4 | -37.4 | -37.6 | -61.2 | -123.9 |
Cash Flow from Financing Activities | -18.4 | -1,175.8 | -47.1 | 90.7 | -101.1 | -164.3 | -107.0 | -117.4 | -0.7 | -30.3 | 104.9 | -133.6 |
Net Cash Inflow / Outflow | -10.5 | -1.7 | 12.0 | 25.5 | -1.6 | 9.0 | -2.1 | -10.3 | -0.9 | -14.1 | 19.7 | -29.5 |
Opening Cash & Cash Equivalents | 50.4 | 52.1 | 40.2 | 14.5 | 16.4 | 7.5 | 9.6 | 20.0 | 20.8 | 35.0 | 15.2 | 44.3 |
Closing Cash & Cash Equivalent | 39.9 | 50.4 | 52.1 | 40.2 | 14.5 | 16.4 | 7.5 | 9.7 | 20.0 | 20.8 | 35.0 | 15.2 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of -2.63, which results in a Negative aspect.
The Industry PCF RATIO stands at 24.29, vs the PCF RATIO of -22.01, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 1,505.0 | 1,430.2 | 1,291.9 | 1,289.3 | 1,152.0 | 1,051.2 | 1,107.0 | 1,407.3 | 1,558.8 | 2,321.7 | 1,324.5 | 1,682.7 | 1,417.6 | 1,820.2 | 1,327.6 | 1,253.6 |
Total Income | 1,561.8 | 1,462.5 | 1,352.7 | 1,439.9 | 1,291.4 | 1,155.7 | 1,229.1 | 1,447.8 | 1,575.4 | 2,342.0 | 1,356.8 | 1,731.7 | 1,436.5 | 1,840.2 | 1,339.5 | 1,433.4 |
Total Expenditure | 1,506.5 | 1,465.8 | 1,395.0 | 1,346.0 | 1,238.4 | 1,089.6 | 1,905.1 | 1,709.2 | 1,440.2 | 2,261.5 | 1,340.0 | 1,673.3 | 1,266.1 | 1,440.1 | 1,102.2 | 1,482.3 |
PBIDT (Excl OI) | -1.5 | -35.6 | -103.1 | -56.7 | -86.4 | -38.4 | -798.1 | -301.9 | 118.6 | 60.2 | -15.5 | 9.4 | 151.5 | 380.1 | 225.4 | -228.7 |
Other Income | 56.8 | 32.3 | 60.8 | 150.6 | 139.4 | 104.5 | 122.1 | 40.5 | 16.6 | 20.3 | 32.3 | 49.0 | 18.9 | 20.0 | 11.9 | 179.8 |
Operating Profit | 55.3 | -3.3 | -42.3 | 93.9 | 53.0 | 66.1 | -676.0 | -261.4 | 135.2 | 80.5 | 16.8 | 58.4 | 170.4 | 400.1 | 237.3 | -48.9 |
Interest | 8.5 | 9.1 | 10.0 | 10.5 | 9.6 | 11.8 | 12.5 | 306.6 | 521.3 | 501.6 | 478.9 | 469.1 | 113.1 | 475.1 | 452.3 | 444.6 |
Exceptional Items | 27.8 | 27.7 | 277.4 | 193.8 | 277.7 | 277.7 | 277.4 | 16,762.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 74.6 | 15.3 | 225.1 | 277.2 | 321.1 | 332.0 | -411.1 | 16,194.1 | -386.1 | -421.1 | -462.1 | -410.7 | 57.3 | -75.0 | -215.0 | -493.5 |
Depreciation | 91.1 | 93.1 | 94.8 | 95.1 | 96.7 | 98.9 | 100.5 | 111.5 | 105.5 | 109.0 | 110.6 | 115.8 | 456.9 | 113.8 | 113.3 | 100.5 |
Profit Before Tax | -16.5 | -77.8 | 130.3 | 182.1 | 224.4 | 233.1 | -511.6 | 16,082.6 | -491.6 | -530.1 | -572.7 | -526.5 | -399.6 | -188.8 | -328.3 | -594.0 |
Tax | 5.5 | 5.1 | 20.5 | 308.9 | 30.7 | 76.1 | 49.8 | 3,707.9 | 0.4 | 0.0 | 0.8 | 14.9 | 0.4 | 0.9 | 3.4 | 91.5 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | -22.0 | -82.9 | 109.8 | -126.8 | 193.7 | 157.0 | -561.4 | 12,374.7 | -492.0 | -530.1 | -573.5 | -541.4 | -400.0 | -189.7 | -331.7 | -685.5 |
Net Profit | -22.0 | -82.9 | 109.8 | -126.8 | 193.7 | 157.0 | -561.4 | 12,374.7 | -492.0 | -530.1 | -573.5 | -541.4 | -400.0 | -194.0 | -341.9 | -698.6 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 | 61.3 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | -0.4 | -1.4 | 1.8 | -2.1 | 3.2 | 2.6 | -9.2 | 202.0 | -8.0 | -8.7 | -9.4 | -8.8 | -6.5 | -3.1 | -5.4 | -11.2 |
Operating Profit Margin | 3.7 | -0.2 | -3.3 | 7.3 | 4.6 | 6.3 | -61.1 | -18.6 | 8.7 | 3.5 | 1.3 | 3.5 | 12.0 | 22.0 | 17.9 | -3.9 |
Net Profit Margin | -1.5 | -5.8 | 8.5 | -9.8 | 16.8 | 14.9 | -50.7 | 879.3 | -31.6 | -22.8 | -43.3 | -32.2 | -28.2 | -10.4 | -25.0 | -54.7 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of 19.13, which results in a Positive aspect.
The Industry Mcap Growth stands at 19.69, vs the Mcap Growth of -44.75, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 154.65 | 161.20 | 146.68 |
R3 | 152.60 | 151.90 | 145.16 |
R2 | 150.55 | 150.20 | 144.66 |
R1 | 147.10 | 146.40 | 144.15 |
Pivot | 145.05 | 144.70 | 145.05 |
S1 | 141.60 | 140.90 | 143.15 |
S2 | 139.55 | 139.20 | 142.64 |
S3 | 136.10 | 135.40 | 142.14 |
S4 | 132.65 | 128.20 | 140.63 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
81.51
Bearish
RSI
45.26
Neutral
ROC
5.59
Bullish
UltimateOscillator
44.24
Neutral
Williams Indicator
-48.78
Neutral
CCI Indicator
102.41
Bearish
MACD
-2,819.05
Bearish
Stochastic Indicator
49.19
Neutral
ATR
6.83
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
13-02-2024 | Quarterly Results |
10-11-2023 | Quarterly Results |
12-08-2023 | Quarterly Results |
30-05-2023 | Audited Results |
14-02-2023 | Quarterly Results |
14-11-2022 | Quarterly Results |
09-08-2022 | Quarterly Results |
18-05-2022 | Audited Results |
14-02-2022 | Quarterly Results |
01-02-2022 | Inter alia, to consider and approve the proposal of raising funds in such manner and on such terms as may be decided by the Board of Directors of the Company and / or its subsidiary company, subject to such regulatory /statutory approvals as may be required. The Board would also consider convening Extra-ordinary General Meeting of its shareholders for seeking their approval in accordance with the relevant provisions of the Act. |
12-11-2021 | Quarterly Results |
23-07-2021 | Quarterly Results |
02-06-2021 | Audited Results |